NBIX vs REG · P/E 45, rev $2.36B vs P/E 34, $12.93B cap
Neurocrine Biosciences Inc (NBIX) versus Regency Centers Corporation (REG) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Regency Centers Corporation (REG) is a reit - retail company listed on US.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
REG does not have a complete income-statement cache yet.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. REG currently screens at market cap $12.93B and trailing P/E 33.5.
Not investment advice. Open the NBIX and REG stock pages for the full models.
Not investment advice.